These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27159756)

  • 1. Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer.
    Chatterjee S; Chen L; Tergas AI; Burke WM; Hou JY; Hu JC; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Obstet Gynecol; 2016 Jun; 127(6):992-1002. PubMed ID: 27159756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.
    Wright JD; Hou JY; Burke WM; Tergas AI; Chen L; Hu JC; Ananth CV; Neugut AI; Hershman DL
    Obstet Gynecol; 2016 Jun; 127(6):985-991. PubMed ID: 27159764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Yamamuro O; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
    Int J Gynecol Cancer; 2012 Sep; 22(7):1143-9. PubMed ID: 22801028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Nasioudis D; Latif NA; Simpkins F; Cory L; Giuntoli RL; Haggerty AF; Morgan MA; Ko EM
    Gynecol Oncol; 2020 Feb; 156(2):315-319. PubMed ID: 31839340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma.
    Swift BE; Covens A; Mintsopoulos V; Parra-Herran C; Bernardini MQ; Nofech-Mozes S; Hogen L
    Int J Gynecol Cancer; 2022 Apr; 32(4):525-531. PubMed ID: 34969829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of care and outcomes for women with uterine cancer and ovarian metastases.
    Jones NL; Huang Y; Chatterjee S; Tergas AI; Burke WM; Hou JY; Deutsch I; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Int J Gynecol Cancer; 2019 Feb; 29(2):365-376. PubMed ID: 30718315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
    Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
    Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer.
    Matsuo K; Machida H; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Enomoto T; Mikami M
    Obstet Gynecol; 2019 Nov; 134(5):1017-1026. PubMed ID: 31599824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
    Richardson MT; Mysona DP; Klein DA; Mann A; Liao CI; Diver EJ; Darcy KM; Tian C; She JX; Ghamande S; Van Le L; Kapp DS; Chan JK
    Gynecol Oncol; 2020 Oct; 159(1):118-128. PubMed ID: 32828578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis.
    Yoshihara M; Tamauchi S; Iyoshi S; Kitami K; Uno K; Mogi K; Kajiyama H
    J Gynecol Oncol; 2021 Sep; 32(5):e66. PubMed ID: 34378361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
    Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
    Dinkelspiel HE; Tergas AI; Zimmerman LA; Burke WM; Hou JY; Chen L; Hillyer G; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2015 May; 137(2):203-9. PubMed ID: 25703674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
    Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
    Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.